Home Latest News Chinese pharmaceutical group to market its products in Pakistan
Latest News - December 6, 2020

Chinese pharmaceutical group to market its products in Pakistan

Badar Uz Zaman, Commercial Consular, Pakistan Embassy Beijing said that Shenyang Biotech and Biomedicine Group, a chinese pharmaceutical enterprise has signed an agreement with Pakistan to market its products in Pakistan. In the next stage, he said, the enterprise will set up gene and cell technology research center in Pakistan which will then be concerted to a university. He said that the center will enhance research capabilities of Pakistani students. Moreover, he also acknowledged China’s role during the pandemic and said that the medical support to Pakistan played critical role in containing the COVID pandemic.

EIJING:

A Chinese enterprise in collaboration with a Pakistani partner will market its products as well as set up a gene and cell research and transformation center in Pakistan.

“Initially, Shenyang Biotech and Biomedicine Group will be marketing its products in Pakistan through Dynamic Engineering Automation Group, and later on they will establish a research laboratory which will ultimately be transformed into a university,” said Badar Uz Zaman, Commercial Consular, Pakistan Embassy Beijing.

“The collaboration between the two companies will be materialized very quickly and we will see the results very soon”, he made these remarks while addressing the cloud signing ceremony for the project held simultaneously in China and Pakistan.

Pakistan’s first national esports tournament to take place in 2021

Badar Uz Zama remarked that Shenyong Biotech was a strong company specializing in pathogen detection, biological reagent and stem cell, etc while Dynamic Engineering and Automation was in the market for the last 20 years.

“The setting up of the research center and the university will facilitate Pakistani students in their research and it will also contribute towards Pakistan’s economy as
well,” he added.

Pakistan, he informed had a strong pharmaceutical industry, and currently, around 750 pharmaceutical companies were working in Pakistan but they are mostly busy manufacturing allopathic medicines.

“We need support from the Chinese side on the vaccine, DNA, and high technology and since this project is being supported by Liaoning’s Provincial Development Reform Commission, we hope to see the materialisation of the project very soon,” he added.

He observed that there was much room for improvement in medical technology in Pakistan.

“China has made important contributions to the world’s fight against the pandemic, we both sides are optimistic about the prospects for cooperation in the field of health care,” he said.

Acknowledging the support of Biotech during Pakistan’s fight against Covid-19, he said, it was the first company which contacted Pakistan Embassy Beijing and donated PCR kits.

CDC shortens recommended quarantine period for coronavirus

Speaking on occasion, Li Junyuan, Deputy Director of Belt and Road Initiative Construction Promotion Center of National Development and Reform Commission, stressed that this collaboration is an important step for China to continue to actively support Pakistan in responding to the epidemic and improving public health care and to make new contributions to building a closer, more beneficial and higher-quality China-Pakistan community with a shared future.

Chairman Biotech, Prof Yin Xiushan emphasized that the project could provide technical support for the research and development of various pathogen detection kits and rapid testing equipment, and effectively enhance the ability of epidemic prevention and control in Pakistan, which is of great significance.

The cloud conference and signing ceremony were attended by officials from both China and Pakistan, two enterprises, banks, and media.

Comments Off on Chinese pharmaceutical group to market its products in Pakistan

Check Also

CPEC’s Success Story: $25 Billion Invested Across 38 Completed Projects

ISLAMABAD: A total of 38 projects worth over $25 billion have been completed and 23 develo…